Netherlands

EQS-News: Encavis Asset Management brings Energy generation and agriculture into harmony: impressive agri-PV plant now part of Encavis Asset Management's portfolio

Retrieved on: 
Thursday, December 7, 2023
Qualifying investor alternative investment fund, Electricity, Bayerische Landesbank, Rabigh 2 IPP, ISIN, United Nations Global Compact, Energy, ISS, ESG, MDAX, Primary energy, Wind, PV, Investment fund, UN, Krishna River Management Board, Plant, CO2, Agriculture, MSCI, Growth, Investment, Acquisition, Renewable energy, Europe, Ticker, Italy, Netherlands

Encavis Asset Management brings Energy generation and agriculture into harmony: impressive agri-PV plant now part of Encavis Asset Management's portfolio

Key Points: 
  • Encavis Asset Management brings Energy generation and agriculture into harmony: impressive agri-PV plant now part of Encavis Asset Management's portfolio
    The issuer is solely responsible for the content of this announcement.
  • Energy generation and agriculture in harmony: impressive agri-PV plant now part of Encavis Asset Management's portfolio
    Neubiberg/Munich, 15 November 2023 – Encavis Asset Management AG (Encavis AM), a leading provider of sustainable energy investments for institutional investors and a subsidiary of the MDAX-listed wind and solar park operator Encavis AG, has acquired an Agri-Photovoltaic plant in the Netherlands on behalf of the Encavis Infrastructure Fund II (EIF II).
  • With this type of PV plant, land use is optimised in such a way that electricity generation and agriculture are combined with each other.
  • Encavis Asset Management AG offers institutional investors tailor-made portfolios and fund solutions for investments in the growth market of Renewable Energies.

EQS-News: Deutsche Postbank Funding Trust III: Half Year Report as of 30th June 2023

Retrieved on: 
Tuesday, November 7, 2023
News, Netherlands, Wet, Security (finance)

Deutsche Postbank Funding Trust III: Half Year Report as of 30th June 2023

Key Points: 
  • Deutsche Postbank Funding Trust III: Half Year Report as of 30th June 2023
    The issuer is solely responsible for the content of this announcement.
  • Deutsche Postbank Funding Trust III hereby announces that the half year report as of 30th June 2023 pursuant to Section 5:25c of the Netherlands Financial Supervision Act (Wet op het financieel toezicht) is available at: https://investor-relations.db.com/creditors/prospectuses/reports-deutsch...
    01.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
  • The issuer is solely responsible for the content of this announcement.
  • The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Urban-Air Port® joins forces with NACO To accelerate vertiport integration into airports globally

Retrieved on: 
Friday, November 3, 2023
Partner, Dallas CBD Vertiport, Gen, UAP, Advanced Air Mobility, Egis Group, Next, Consultant, Foster and Partners, Air One, Certification, UAP Old Mutual Tower, Memorandum of understanding, Royal, EASA, Aviation, Growth, Partnership, Foster, Collaboration, Netherlands, Noise, Safety, Aircraft, NACO, CAA, Airport, FAA, Transport, Airline

Collaboration bolsters Urban-Air Ports' efforts to deploy Next Gen Air One vertiport technology at regional and international airports around the world.

Key Points: 
  • Collaboration bolsters Urban-Air Ports' efforts to deploy Next Gen Air One vertiport technology at regional and international airports around the world.
  • NACO will further support UAP on airport land-use planning, regional vertiport network business modelling, eVTOL demand simulation and surface transport intermodal connectivity modelling.
  • NACO and UAP will also explore special systems for the integration of UAP vertiports to support regulatory pathways for the first use cases: eVTOL (electric vertical take-off and landing) flights to/from airports.
  • NACO recognises UAP's pioneering AirOne vertiport technology, industry-leading experience and proprietary technology as pivotal to the success of the wider adoption of vertiports at airports.

Urban-Air Port® joins forces with NACO To accelerate vertiport integration into airports globally.

Retrieved on: 
Friday, November 3, 2023
Partner, Dallas CBD Vertiport, Gen, UAP, Advanced Air Mobility, Egis Group, Next, Consultant, Foster and Partners, Air One, Certification, UAP Old Mutual Tower, Memorandum of understanding, Royal, EASA, Aviation, Growth, Partnership, Foster, Collaboration, Netherlands, Noise, Safety, Aircraft, NACO, CAA, Airport, FAA, Transport, Airline

Collaboration bolsters Urban-Air Ports' efforts to deploy Next Gen Air One vertiport technology at regional and international airports around the world.

Key Points: 
  • Collaboration bolsters Urban-Air Ports' efforts to deploy Next Gen Air One vertiport technology at regional and international airports around the world.
  • NACO will further support UAP on airport land-use planning, regional vertiport network business modelling, eVTOL demand simulation and surface transport intermodal connectivity modelling.
  • NACO and UAP will also explore special systems for the integration of UAP vertiports to support regulatory pathways for the first use cases: eVTOL (electric vertical take-off and landing) flights to/from airports.
  • NACO recognises UAP's pioneering AirOne vertiport technology, industry-leading experience and proprietary technology as pivotal to the success of the wider adoption of vertiports at airports.

New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo Patients

Retrieved on: 
Wednesday, October 11, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Congress, Journal of the European Academy of Dermatology and Venereology, Autoimmunity, Vitiligo, BID, Abstract, Ciclosporin, Inflammation, Depigmentation, Prevalence, Azathioprine, Pigmentation disorder, Melanocyte, American Academy, Week, University, JAK, AAD, Netherlands, Skin, LTE, Patient, Pharmaceutical industry, Dermatology, Venereology, Incyte

These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.

Key Points: 
  • These long-term data highlight encouraging updates for an important sub-group of patients with nonsegmental vitiligo, those who initially showed limited or no response to treatment,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte.
  • Opzelura is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
  • The overall prevalence of the condition is estimated to be approximately 2-3 million2, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo3.
  • Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 304.

Neoss® Group receives EU Medical Device Regulation (MDR) certifications for implants and abutments

Retrieved on: 
Thursday, October 12, 2023
European, Certification, BSI Group, Legislation, MDR, Database, Regulation, Quality management system, Notified body, Netherlands, BSI, MDD, European Medical Devices Industry Group, Patient, Medical device, EU

ZÜRICH, Oct. 12, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments.

Key Points: 
  • ZÜRICH, Oct. 12, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments.
  • This signifies that Neoss Group's Quality Management System and its implants and abutments meet the requirements of the new MDR implemented by the European Union.
  • The new EU Medical Devices Regulation 2017/745 (MDR) replaces the former European Medical Device Directive 93/42/EEC (MDD), and brings EU legislation into line with technical advances, changes in medical science and progress in law-making.
  • The new MDR regulation contains a series of important improvements including establishing a comprehensive and accessible EU database on medical devices with a device traceability system based on a unique device identification.

Neoss® Group receives EU Medical Device Regulation (MDR) certifications for implants and abutments

Retrieved on: 
Thursday, October 12, 2023
European, Certification, BSI Group, Legislation, MDR, Database, Regulation, Quality management system, Notified body, Netherlands, BSI, MDD, European Medical Devices Industry Group, Patient, Medical device, EU

ZÜRICH, Oct. 12, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments.

Key Points: 
  • ZÜRICH, Oct. 12, 2023 /PRNewswire/ -- Neoss Group, a leading innovator in dental implant solutions, is proud to announce that it has received EU Medical Device Regulation (MDR) certification by its Notified Body, the BSI Group, the Netherlands B.V. for its implants and abutments.
  • This signifies that Neoss Group's Quality Management System and its implants and abutments meet the requirements of the new MDR implemented by the European Union.
  • The new EU Medical Devices Regulation 2017/745 (MDR) replaces the former European Medical Device Directive 93/42/EEC (MDD), and brings EU legislation into line with technical advances, changes in medical science and progress in law-making.
  • The new MDR regulation contains a series of important improvements including establishing a comprehensive and accessible EU database on medical devices with a device traceability system based on a unique device identification.

EQS-News: Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Cleveland Clinic, Short course immune induction therapy, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Pharmaceutical industry, Pharmacovigilance

NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:

Key Points: 
  • NEW YORK, October 4, 2023 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following scientific conferences in October:
    October 11-13: MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting.
  • The poster presentation will be accessible on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

Immunic to Participate in Scientific Conferences in October

Retrieved on: 
Wednesday, October 4, 2023
Abstract, Cleveland Clinic, Metabolism, IBD, United European Gastroenterology, Biotechnology, UEG, Regeneration, Multiple sclerosis, Doctor of Philosophy, Netherlands, MS, Hepatology, MD, Gastroenterology, Neurofilament, Human, Regulatory affairs, Montreal Neurological Institute and Hospital, Research, Coeliac disease, Treatment, Vaccine, Pharmacovigilance, Short course immune induction therapy

The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Title: Reduction in Neurofilament Light Chain by Vidofludimus Calcium: The EMPhASIS Study
    October 14-17: UEG (United European Gastroenterology) Week 2023.
  • The presentations will be accessible on the "Events and Presentations" section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Darius-Jean Namdjou, PhD, Head of Regulatory Affairs and Pharmacovigilance at Immunic, will speak during two sessions at this summit in Brussels, Belgium.

Albemarle Corp. to Pay SEC More Than $103 Million to Settle FCPA Violations

Retrieved on: 
Friday, September 29, 2023
Jordan Investment Commission, Environmental crime, Justice, IRS Criminal Investigation, U.S. Department of Commerce Office of Security, Investment, Coast Guard Investigative Service, Fraud, Albemarle Corporation, U.S. Department of Justice Office of Legislative Affairs, Foreign Corrupt Practices Act, Netherlands, Private prosecution, Order, Australian Securities and Investments Commission v Rich, FCPA, Security (finance), United States Department of Justice Criminal Division, Zawar Farid, Securities and Exchange Board of India, United Arab Emirates

Washington, D.C.--(Newsfile Corp. - September 29, 2023) - The Securities and Exchange Commission today announced that Charlotte-based Albemarle Corporation, a global specialty chemicals company, agreed to pay more than $103.6 million to settle the SEC’s charges that it violated the anti-bribery, recordkeeping, and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA).

Key Points: 
  • Washington, D.C.--(Newsfile Corp. - September 29, 2023) - The Securities and Exchange Commission today announced that Charlotte-based Albemarle Corporation, a global specialty chemicals company, agreed to pay more than $103.6 million to settle the SEC’s charges that it violated the anti-bribery, recordkeeping, and internal accounting controls provisions of the Foreign Corrupt Practices Act (FCPA).
  • Albemarle has agreed to cease and desist from committing or causing any future violations of these provisions and to pay disgorgement of more than $81.8 million plus prejudgment interest of more than $21.7 million, totaling over $103.6 million.
  • In a parallel action, the U.S. Department of Justice announced today it has entered into a non-prosecution agreement in which Albemarle agreed to pay a $99 million criminal fine and to a forfeiture of approximately $98 million, of which $81.8 million will be satisfied by the company’s payment of disgorgement pursuant to the SEC Order.
  • The SEC’s investigation was conducted by Christine Neal, M. Shahriar Masud, and Brittany Prelogar of the SEC’s FCPA Unit, with assistance from Fernando Campoamor.